Comparing the current results to its competitors, Crinetics Pharmaceuticals Inc reported Revenue increase in the 2 quarter 2026 by 2336.28 % year on year. The sales growth was above Crinetics Pharmaceuticals Inc 's competitors' average revenue growth of 6.63 %, achieved in the same quarter.
Crinetics Pharmaceuticals Inc , slower than the average decrease reported by the company's competitors of -0.49 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -0.49 %
Crinetics Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The company is developing a once-daily oral SST2R agonist for acromegaly intended to provide biochemical and symptom control with improved convenience. It has licensed commercialization rights for paltusotine in Japan to SKK and may pursue additional global partnerships. The company focuses on endocrine diseases and related tumors, developing novel small molecule product candidates targeting peptide hormone G protein-coupled receptors (GPCRs) to create orally bioavailable and potentially more selective therapeutics. The market for new drugs in this area is competitive, with potential competition from various pharmaceutical and biotechnology companies worldwide. Competitors may develop safer, more effective, or more convenient products and may obtain regulatory approvals more rapidly. Key factors in competition include efficacy, safety, and convenience. In acromegaly treatment, objectives include reducing serum growth hormone (GH), normalizing insulin-like growth factor 1 (IGF-1), alleviating symptoms, and reducing or stabilizing tumors, with surgery often serving as the initial treatment option.
Due to outstanding performance in Overall company, revenue grew by 2336.28 % Crinetics Pharmaceuticals Inc improved its market share, to approximately 0.13 %.
June 10, 2024
Crinetics Pharmaceuticals Enhances Talent Acquisition with Strategic Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, June 10, 2024 In a strategic move to attract top-tier talent, Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) has disclosed an important development in its ongoing efforts to enrich its human capital. On June 10, 2024, the Compensation Committee of Crinetics Board of Directors sanctioned non-qualified stock option awards, entailing the acquisition of an aggregate of 158,000 shares of the company s common stock. The recipients of these inducement grants are nine newly appointed non-executive employees, who are being welcomed into the organization through the Crinetics Phar...
June 3, 2024
Crinetics Presents Compelling Data Highlighting Potential of Paltusotine in Treating Acromegaly and Carcinoid SyndromeCrinetics Pharmaceuticals has recently unveiled promising data at ENDO 2024, providing further evidence that positions paltusotine as a potential first-choice treatment option for acromegaly and carcinoid syndrome. The data presentation, marked as the first scientific disclosure of the PATHFNDR-2 acromegaly safety and efficacy study, adds significant weight to earlier positive topline announcements. Paltusotine’s Role in Acromegaly TreatmentAcromegaly, a hormonal disorder often resulting from an excess of growth hormone, presents considerable management challenges. The latest findings from...
May 22, 2024
In a recent announcement, Crinetics Pharmaceuticals, a clinical-stage pharmaceutical company dedicated to addressing endocrine diseases and endocrine-related tumors, informed the public that the late-breaking abstracts for the Endocrine Society s annual meeting (ENDO 2024) have been released earlier than anticipated. This development signifies a significant step forward in the discovery, development, and commercialization of novel therapeutics for endocrine disorders. Crinetics Pharmaceuticals groundbreaking research discussed in these abstracts holds great promise in revolutionizing the treatment landscape for patients suffering from endocrine diseases. Crinetics Pharmaceuticals Focus on Endocrine Disease...
Crinetics Pharmaceuticals Inc., a leading biopharmaceutical company, recently announced positive initial findings from an ongoing open-label Phase 2 study of their latest innovative drug, Paltusotine. This breakthrough drug is being developed for the treatment of Carcinoid Syndrome, a rare condition characterized by symptoms such as frequent bowel movements and flushing episodes. The study reported significant reductions in both the frequency and intensity of these distressing symptoms in patients. Such promising results indicate the potential of Paltusotine to revolutionize the treatment landscape for Carcinoid Syndrome patients, providing them with a much-needed reprieve from their debilitati...
Publicly Traded Peers of Crinetics Pharmaceuticals Inc
Acadia Pharmaceuticals Inc Share Performance
+1.79%
This Year
Acadia Pharmaceuticals Inc
Profile
Acadia Pharmaceuticals Inc's business model centers around the research, development, and commercialization of innovative medicines for diseases related to the central nervous system. They collaborate with a network of partners and employ a combination of in-house research and licensing agreements to discover and develop drug candidates. Their primary revenue stream comes from the sales of approved products, with a focus on providing effective therapeutic options for patients with unmet medical needs.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
Sources:
Crinetics Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Crinetics Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
